Literature DB >> 9377590

Preclamol and parkinsonian fluctuations.

Z Pirtosek1, M Merello, A Carlsson, G Stern.   

Abstract

Preclamol, the (-)enantiomer of 3-PPP (= 3(3-hydroxyphenyl)-N-n-propyl piperidine), has a selective dopamine autoreceptor- and postsynaptic mixed agonist-antagonist profile. Its action on patients with disabling on-off parkinsonian fluctuations has been studied and compared with those of placebo and subcutaneous apomorphine. Preclamol had a mild but unequivocal antiakinetic effect, less than that caused by subcutaneous apomorphine, but it provoked less dyskinesia. Further studies to explore the therapeutic potential of preclamol seem justified.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 9377590

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  4 in total

1.  Dopamine agonist 3-PPP fails to protect against MPTP-induced toxicity.

Authors:  Dhanasekaran Muralikrishnan; Manuchair Ebadi; Holly M Brown-Borg
Journal:  Neurochem Res       Date:  2004-02       Impact factor: 3.996

2.  Extrapyramidalism in Alzheimer's disease: prevalence, psychiatric, and neuropsychological correlates.

Authors:  M Merello; L Sabe; A Teson; R Migliorelli; M Petracchi; R Leiguarda; S Starkstein
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-12       Impact factor: 10.154

Review 3.  A dopaminergic deficit hypothesis of schizophrenia: the path to discovery.

Authors:  Arvid Carlsson; Maria L Carlsson
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

4.  Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson's disease.

Authors:  J Guridi; R González-Redondo; J A Obeso
Journal:  Parkinsons Dis       Date:  2012-10-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.